Latest Breaking News On - Anat cohen dayag - Page 8 : comparemela.com

Compugen (CGEN) to Receive $7 5M Milestone Payment Triggered by AstraZeneca s Phase 2 Initiation of PD-1/TIGIT Bispecific

Compugen (CGEN) to Receive $7 5M Milestone Payment Triggered by AstraZeneca s Phase 2 Initiation of PD-1/TIGIT Bispecific
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Tel avivYvonne naughtonExchange commissionCompugen ltdSecurities exchangeTel aviv stock exchangeWall streetAnat cohen dayagChief executive officerCompugen astrazeneca licenseSouth san franciscoSecurities actSecurities exchange actPrivate securities litigation reform actAnnual reportInvestor relations

Compugen Reports Third Quarter 2022 Results

New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor.

Tel avivYvonne naughtonCorporate communications compugen ltdStock exchangeExchange commissionSecurities exchangePrnewswire compugen ltdAnat cohen dayagChief executive officerSouth san franciscoSecurities actSecurities exchange actPrivate securities litigation reform actAnnual reportInvestor relationsCorporate communications compugen

Compugen to Participate in the Stifel Healthcare Conference

/PRNewswire/ Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today.

New yorkUnited statesTel avivYvonne naughtonCompugen ltdCorporate communicationsStock exchangePrnewswire compugen ltdAnat cohen dayagInvestor relationsSouth san franciscoCompugen ltdHealth care amp hospitalsMedical pharmaceuticalsData analyticsComputer amp electronics

Israel: An Untapped Biotech Investment Opportunity

With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem. Venture capitalists would do well to pay attention.

United statesNew jerseyUnited kingdomTel avivYochi slonimAvi veidmanCohen dayagMichael riceNuvectis pharmaInnovation authorityWeizmann institute of scienceCompugen ltdIsrael defenseTel aviv universityTeva pharmaceuticalsLifesci advisors

Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer

/PRNewswire/ Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today.

Israel generalTel avivAlberto sessaYvonne naughtonCorporate communications compugen ltdStock exchangeMaster of business administrationHebrew university of jerusalemWorldwide groupPrnewswire compugen ltdChief financial officerAnat cohen dayagChief executive officerBusiness administrationHebrew universitySouth san francisco